The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer.

Abstract

Review of clinical data from 350 patients with small-cell lung cancer (SCLC) revealed hyponatremia (sodium less than 130 mEq/L) attributable to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in 40 patients (11%). Although hyponatremia was severe in most instances (median, sodium 117 mEq/L), symptoms attributable to water intoxication were identified in only 27% of hyponatremic episodes. Development of SIADH showed no correlation with clinical stage, distribution of metastatic sites, sex, or histologic subtype of small-cell carcinoma. SIADH occurred most often with initial presentation (33 of 40), and resolved promptly (less than 3 weeks) with initiation of combination chemotherapy in 80% of evaluable patients. The presence of SIADH did not influence response to chemotherapy or overall survival as an independent variable. However, in five patients profound hyponatremia developed immediately following primary cytotoxic therapy (range, one to five days). Despite initial control of SIADH, dilutional hyponatremia recurred in 70% of patients with tumor progression. Our findings suggest that development of clinically demonstrable SIADH in patients with SCLC is dependent on functional properties of the neoplastic cells, rather than tumor burden or metastatic site. The potential for development of clinically significant hyponatremia early in the course of cytotoxic therapy emphasizes the need to closely monitor patients, particularly those receiving chemotherapy regimens requiring substantial intravenous hydration.

• Authors: A F List, J D Hainsworth, B W Davis, K R Hande, F A Greco, D H Johnson
• Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 4 Issue 8 Pg. 1191-8 (Aug 1986) ISSN: 0732-183X [Print] United States
• PMID: 3016206 (Publication Type: Journal Article)

Chemical References

• Vasopressins
• Sodium

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Carcinoma, Small Cell (metabolism, pathology, therapy)
• Female
• Inappropriate ADH Syndrome (metabolism)
• Lung Neoplasms (metabolism, pathology, therapy)
• Male
• Neoplasm Metastasis
• Neoplasm Staging
• Osmolar Concentration
• Paraneoplastic Endocrine Syndromes (metabolism)
• Sodium (blood, urine)
• Vasopressins (blood)